330 related articles for article (PubMed ID: 21466769)
1. Investigations of the endocannabinoid system in adipose tissue: effects of obesity/ weight loss and treatment options.
Bennetzen MF
Dan Med Bull; 2011 Apr; 58(4):B4269. PubMed ID: 21466769
[TBL] [Abstract][Full Text] [Related]
2. Investigations of the human endocannabinoid system in two subcutaneous adipose tissue depots in lean subjects and in obese subjects before and after weight loss.
Bennetzen MF; Wellner N; Ahmed SS; Ahmed SM; Diep TA; Hansen HS; Richelsen B; Pedersen SB
Int J Obes (Lond); 2011 Nov; 35(11):1377-84. PubMed ID: 21326208
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
4. Role of the endocannabinoid system in energy balance regulation and obesity.
Cota D
Front Horm Res; 2008; 36():135-145. PubMed ID: 18230900
[TBL] [Abstract][Full Text] [Related]
5. The challenge of treating obesity: the endocannabinoid system as a potential target.
Isoldi KK; Aronne LJ
J Am Diet Assoc; 2008 May; 108(5):823-31. PubMed ID: 18442506
[TBL] [Abstract][Full Text] [Related]
6. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia.
Matias I; Gonthier MP; Orlando P; Martiadis V; De Petrocellis L; Cervino C; Petrosino S; Hoareau L; Festy F; Pasquali R; Roche R; Maj M; Pagotto U; Monteleone P; Di Marzo V
J Clin Endocrinol Metab; 2006 Aug; 91(8):3171-80. PubMed ID: 16684820
[TBL] [Abstract][Full Text] [Related]
7. The endocannabinoid system: a new target for the regulation of energy balance and metabolism.
Després JP
Crit Pathw Cardiol; 2007 Jun; 6(2):46-50. PubMed ID: 17667864
[TBL] [Abstract][Full Text] [Related]
8. Effect of the cannabinoid receptor-1 antagonist rimonabant on inflammation in mice with diet-induced obesity.
Wang Q; Perrard XD; Perrard JL; Mansoori A; Smith CW; Ballantyne CM; Wu H
Obesity (Silver Spring); 2011 Mar; 19(3):505-13. PubMed ID: 20885384
[TBL] [Abstract][Full Text] [Related]
9. Role of the endocannabinoid system in metabolic control.
Wang J; Ueda N
Curr Opin Nephrol Hypertens; 2008 Jan; 17(1):1-10. PubMed ID: 18090663
[TBL] [Abstract][Full Text] [Related]
10. Effects on food intake and blood lipids of cannabinoid receptor 1 antagonist treatment in lean rats.
Bennetzen MF; Nielsen MP; Richelsen B; Pedersen SB
Obesity (Silver Spring); 2008 Nov; 16(11):2451-5. PubMed ID: 18719671
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of cannabinoid receptors and glucose metabolism.
Scheen AJ; Paquot N
Curr Opin Clin Nutr Metab Care; 2008 Jul; 11(4):505-11. PubMed ID: 18542014
[TBL] [Abstract][Full Text] [Related]
12. Contribution of CB1 blockade to the management of high-risk abdominal obesity.
Després JP; Lemieux I; Alméras N
Int J Obes (Lond); 2006 Apr; 30 Suppl 1():S44-52. PubMed ID: 16570106
[TBL] [Abstract][Full Text] [Related]
13. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells.
Bensaid M; Gary-Bobo M; Esclangon A; Maffrand JP; Le Fur G; Oury-Donat F; Soubrié P
Mol Pharmacol; 2003 Apr; 63(4):908-14. PubMed ID: 12644592
[TBL] [Abstract][Full Text] [Related]
14. Activation of the peripheral endocannabinoid system in human obesity.
Engeli S; Böhnke J; Feldpausch M; Gorzelniak K; Janke J; Bátkai S; Pacher P; Harvey-White J; Luft FC; Sharma AM; Jordan J
Diabetes; 2005 Oct; 54(10):2838-43. PubMed ID: 16186383
[TBL] [Abstract][Full Text] [Related]
15. Role of the endocannabinoid system in management of patients with type 2 diabetes mellitus and cardiovascular risk factors.
Davis SN; Perkins JM
Endocr Pract; 2007; 13(7):790-804. PubMed ID: 18194939
[TBL] [Abstract][Full Text] [Related]
16. The endocannabinoid system: novel pathway for cardiometabolic Risk-factor reduction.
Woods SC
JAAPA; 2007 Nov; Suppl Endocannabinoid():7-10. PubMed ID: 18047036
[TBL] [Abstract][Full Text] [Related]
17. Endocannabinoid system and cardio-metabolic risk.
Loh KY; Kew ST
Med J Malaysia; 2008 Oct; 63(4):348-50; quiz 351. PubMed ID: 19385504
[TBL] [Abstract][Full Text] [Related]
18. [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].
Ducobu J; Sternon J
J Pharm Belg; 2005; 60(3):89-91. PubMed ID: 16252510
[TBL] [Abstract][Full Text] [Related]
19. The endocannabinoid system: a promising target for the management of type 2 diabetes.
Scheen AJ
Curr Protein Pept Sci; 2009 Feb; 10(1):56-74. PubMed ID: 19275673
[TBL] [Abstract][Full Text] [Related]
20. Anti-obesity effects of the combined administration of CB1 receptor antagonist rimonabant and melanin-concentrating hormone antagonist SNAP-94847 in diet-induced obese mice.
Verty AN; Lockie SH; Stefanidis A; Oldfield BJ
Int J Obes (Lond); 2013 Feb; 37(2):279-87. PubMed ID: 22473329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
